Pharmaceuticals, Biotechnology and Life Sciences
Pfizer and Eli lilly have announced top-line results from a Phase 3 study evaluating tanezumab 2.5mg and 5 mg.
Veracyte has named Alfred “Freddie” Bowie, Jr., Ph.D., as vicepresident, corporate and business development.
Teva has launched generic version of VESIcare (solifenacin succinate) Tablets, 5 mg and 10 mg, in the U.S.
Rising Pharma Holdings has completed the purchase of the assets of RisingPharmaceuticals and Rising’s subsidiaries on a cash-free and debt-freebasis.
Preclinical studies indicatethat targeting both E-selectin and CXCR4 with a single compound couldimprove efficacy in the treatment of cancers that involve the bonemarrow such as AML and multiple myeloma or in solid tumors thatmetastasize to the bone, such as prostate cancer and breast cancer.
Novus said the results from single-dose phase 1 studies met theprimary objectives and demonstrated a favorable safety and tolerabilityprofile
Aura Biosciences’ lead productcandidate for the primary treatment of primary choroidal melanoma, willbe highlighted in a poster presentation at the Association for Researchin Vision and Ophthalmology (ARVO) 2019 Annual Meeting
BELRAPZO is indicated for the treatment of patients with indolent B-cellnon-Hodgkin lymphoma (NHL) that has progressed during or within sixmonths of treatment with rituximab or a rituximab-containing regimen.
many patients with advancedrenal cell carcinoma need additional treatment options that can helpimprove survival outcomes
The license allows the current FSD facility to supply and sell cannabisproducts. The company expects receiving the amended sales licensethat will include the sale of dried and fresh cannabis flower in thenear future.